Publications by authors named "A Caillaud"
Article Synopsis
- - The liver is crucial for managing lipoproteins, and creating effective lipid-lowering therapies requires advanced in vitro models that mimic liver functions better than current hepatocyte-like cells (HLCs).
- - Researchers aimed to enhance HLC maturation by using a 3D model with Biomimesys®, which allows human-induced pluripotent stem cells (hiPSCs) to form functional liver organoids.
- - After a 28-day maturation, the liver organoids showed improved gene expression, better cell organization, and significant functional abilities, such as lipid accumulation and production of essential proteins, offering a valuable tool for studying lipoprotein metabolism.
The pursuit of materials with enhanced functionality has led to the emergence of metamaterials-artificially engineered materials whose properties are determined by their structure rather than composition. Traditionally, the building blocks of metamaterials are arranged in fixed positions within a lattice structure. However, recent research has revealed the potential of mixing disconnected building blocks in a fluidic medium.
View Article and Find Full Text PDFElevated circulating lipoprotein(a) (Lp(a)) is a genetically determined risk factor for coronary artery disease and aortic valve stenosis (Tsimikas, 2017). Importantly, the LPA gene, which encodes the apolipoprotein(a) (protein-component of Lp(a)), is missing in most species, and human liver cell-lines do not secrete Lp(a). There is a need for the development of human in vitro models suitable for investigating biological mechanisms involved in Lp(a) metabolism.
View Article and Find Full Text PDFArticle Synopsis
- Hereditary erythrocytosis is a rare condition with excessive red blood cell production, and a study involved 2,160 patients across Europe focusing on the EGLN1 gene.
- Researchers identified 39 mutations in the EGLN1 gene, including one deletion, which encodes the PHD2 enzyme that regulates the hypoxia-inducible factor.
- The study assessed the effects of these mutations through various methods, identifying 16 as pathogenic, and highlighted the importance of collaborative research in addressing rare genetic disorders.
Background: The Canadian Bleeding Disorders Registry (CBDR) is a source of real-world data for Canadian patients with hemophilia B. Nonacog beta pegol (N9-GP), an extended half-life (EHL) recombinant factor IX (FIX) concentrate, was awarded a Canadian Blood Services contract in 2018 and subsequently made available across Canada (except Québec) to adult patients. For most patients already on another EHL FIX treatment, a switch to N9-GP occurred.
View Article and Find Full Text PDF